{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:24:05Z","timestamp":1787955845992,"version":"build-2784847793"},"reference-count":55,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,2,17]]},"published-print":{"date-parts":[[2026,6]]},"DOI":"10.2967\/jnumed.125.271302","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:15:17Z","timestamp":1774541717000},"page":"943-949","source":"Crossref","is-referenced-by-count":2,"title":["Delta-like Ligand 3Directed\n                    <sup>225<\/sup>\n                    Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models"],"prefix":"10.2967","volume":"67","author":[{"given":"Tran T.","family":"Hoang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Ingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana C.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas M.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"De Gregorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Welk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bodei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Tendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"2026060105301018000_67.6.943.1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac9459"},{"key":"2026060105301018000_67.6.943.2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200702009"},{"key":"2026060105301018000_67.6.943.3","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq529"},{"key":"2026060105301018000_67.6.943.4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav0891"},{"key":"2026060105301018000_67.6.943.5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1278"},{"key":"2026060105301018000_67.6.943.6","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1186\/s12967-024-05568-y","article-title":"DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models","volume":"22","author":"Lin","year":"2024","journal-title":"J Transl Med."},{"key":"2026060105301018000_67.6.943.7","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol."},{"key":"2026060105301018000_67.6.943.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263221"},{"key":"2026060105301018000_67.6.943.9","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01464-y"},{"key":"2026060105301018000_67.6.943.10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02070-z"},{"key":"2026060105301018000_67.6.943.11","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.jtho.2021.03.012","article-title":"Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage SCLC: results from the phase 3 MERU study","volume":"16","author":"Johnson","year":"2021","journal-title":"J Thorac Oncol."},{"key":"2026060105301018000_67.6.943.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1133"},{"key":"2026060105301018000_67.6.943.13","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study","volume":"16","author":"Blackhall","year":"2021","journal-title":"J Thorac Oncol."},{"key":"2026060105301018000_67.6.943.14","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1158\/1078-0432.CCR-21-1533","article-title":"Radioimmunotherapy targeting delta-like ligand 3 in small cell lung cancer exhibits antitumor efficacy with low toxicity","volume":"28","author":"Tully","year":"2022","journal-title":"Clin Cancer Res."},{"key":"2026060105301018000_67.6.943.15","doi-asserted-by":"crossref","first-page":"e2203820119","DOI":"10.1073\/pnas.2203820119","article-title":"Delta-like ligand 3targeted radioimmunotherapy for neuroendocrine prostate cancer","volume":"119","author":"Korsen","year":"2022","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2026060105301018000_67.6.943.16","doi-asserted-by":"crossref","first-page":"8575","DOI":"10.1200\/JCO.2023.41.16_suppl.8575","article-title":"A theranostic approach: imaging and therapy of delta-like ligand 3expressing small cell lung cancers [abstract]","volume":"41","author":"Tendler","year":"2023","journal-title":"J Clin Oncol."},{"key":"2026060105301018000_67.6.943.17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/pharmaceutics13010049","article-title":"Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications","volume":"13","author":"Nelson","year":"2020","journal-title":"Pharmaceutics."},{"key":"2026060105301018000_67.6.943.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.204651"},{"key":"2026060105301018000_67.6.943.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.186338"},{"key":"2026060105301018000_67.6.943.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178673"},{"key":"2026060105301018000_67.6.943.21","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1200\/JCO.1993.11.2.294","article-title":"Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias","volume":"11","author":"Schwartz","year":"1993","journal-title":"J Clin Oncol."},{"key":"2026060105301018000_67.6.943.22","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood.V100.4.1233.h81602001233_1233_1239","article-title":"Targeted alpha particle immunotherapy for myeloid leukemia","volume":"100","author":"Jurcic","year":"2002","journal-title":"Blood."},{"key":"2026060105301018000_67.6.943.23","doi-asserted-by":"publisher","DOI":"10.1039\/C3CS60304K"},{"key":"2026060105301018000_67.6.943.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.122.265166"},{"key":"2026060105301018000_67.6.943.25","doi-asserted-by":"crossref","first-page":"TPS288","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS288","article-title":"A phase I\/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA [abstract]","volume":"41","author":"Nauseef","year":"2023","journal-title":"J Clin Oncol."},{"key":"2026060105301018000_67.6.943.26","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.23.00573","article-title":"Prostate-specific membrane antigen-targeting alpha emitter via antibody delivery for metastatic castration-resistant prostate cancer: a phase I dose-escalation study of 225Ac-J591","volume":"42","author":"Tagawa","year":"2024","journal-title":"J Clin Oncol."},{"key":"2026060105301018000_67.6.943.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.138347"},{"key":"2026060105301018000_67.6.943.28","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1021\/cbmi.3c00067","article-title":"225Ac-labeled antibody for fibroblast activation protein-targeted alpha therapy","volume":"1","author":"Song","year":"2023","journal-title":"Chem Biomed Imaging."},{"key":"2026060105301018000_67.6.943.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8043(02)00167-7"},{"key":"2026060105301018000_67.6.943.30","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1021\/acs.molpharmaceut.0c00703","article-title":"Evaluating 225Ac and 177Lu radioimmunoconjugates against antibodydrug conjugates for small-cell lung cancer","volume":"17","author":"Lakes","year":"2020","journal-title":"Mol Pharm."},{"key":"2026060105301018000_67.6.943.31","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201709532"},{"key":"2026060105301018000_67.6.943.32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1650"},{"key":"2026060105301018000_67.6.943.33","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.056036"},{"key":"2026060105301018000_67.6.943.34","doi-asserted-by":"publisher","DOI":"10.2307\/3579579"},{"key":"2026060105301018000_67.6.943.35","first-page":"7","article-title":"ICRP publication 107. Nuclear decay data for dosimetric calculations","volume":"38","author":"Eckerman","year":"2008","journal-title":"Ann ICRP."},{"key":"2026060105301018000_67.6.943.36","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.2967\/jnumed.121.262751","article-title":"Normal-tissue tolerance to radiopharmaceutical therapies, the knowns and the unknowns","volume":"62(suppl 3)","author":"Wahl","year":"2021","journal-title":"J Nucl Med."},{"key":"2026060105301018000_67.6.943.37","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet."},{"key":"2026060105301018000_67.6.943.38","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1039\/D0TB02911D","article-title":"A short PEG linker alters the in vivo pharmacokinetics of trastuzumab to yield high-contrast immuno-PET images","volume":"9","author":"Lee","year":"2021","journal-title":"J Mater Chem B."},{"key":"2026060105301018000_67.6.943.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2018.07.007"},{"key":"2026060105301018000_67.6.943.40","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1158\/1078-0432.CCR-23-3746","article-title":"Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-Macropa-pelgifatamab): a targeted alpha therapy for prostate cancer","volume":"30","author":"Schatz","year":"2024","journal-title":"Clin Cancer Res."},{"key":"2026060105301018000_67.6.943.41","first-page":"241995","article-title":"Lead-212 radio-DARPin therapeutic (RDT) targeting delta-like ligand 3 (DLL3) shows promising preclinical antitumor efficacy and tolerability in small cell lung cancer (SCLC)","volume":"65(suppl 2)","author":"Lizak","year":"2024","journal-title":"J Nucl Med."},{"key":"2026060105301018000_67.6.943.42","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0299"},{"key":"2026060105301018000_67.6.943.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8051(99)00024-4"},{"key":"2026060105301018000_67.6.943.44","doi-asserted-by":"publisher","DOI":"10.7150\/thno.92742"},{"key":"2026060105301018000_67.6.943.45","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/1078-0432.CCR-22-3291","article-title":"Treatment of prostate cancer with CD46-targeted 225Ac alpha particle radioimmunotherapy","volume":"29","author":"Bidkar","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2026060105301018000_67.6.943.46","doi-asserted-by":"publisher","DOI":"10.1293\/tox.27.1S"},{"key":"2026060105301018000_67.6.943.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.07.1714"},{"key":"2026060105301018000_67.6.943.48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2150"},{"key":"2026060105301018000_67.6.943.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2024.108976"},{"key":"2026060105301018000_67.6.943.50","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266388"},{"key":"2026060105301018000_67.6.943.51","unstructured":"Alvarez NH Bauer D Michel AL Carter LM Lewis JS . Targeted alpha therapy with [225Ac]Ac-Macropa-isatuximab for CD38-positive hematological malignancies [preprint]. https:\/\/www.biorxiv.org\/content\/10.1101\/2024.11.01.621584v1. Accessed March 5, 2026."},{"key":"2026060105301018000_67.6.943.52","doi-asserted-by":"crossref","unstructured":"Bauer D De Gregorio R Pratt EC Bell A Michel A Lewis JS . Exploring the PET in vivo generator 134Ce as a theranostic match for 225Ac [preprint]. bioRxiv. April 28, 2024.","DOI":"10.1007\/s00259-024-06811-w"},{"key":"2026060105301018000_67.6.943.53","doi-asserted-by":"crossref","first-page":"108867","DOI":"10.1016\/j.isci.2024.108867","article-title":"Time- and sex-dependent delayed effects of acute radiation exposure manifest via miRNA dysregulation","volume":"27","author":"Holmes-Hampton","year":"2024","journal-title":"iScience."},{"key":"2026060105301018000_67.6.943.54","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.3390\/biomedicines11102812","article-title":"DLL3 is a prognostic and potentially predictive biomarker for immunotherapy linked to PD\/PD-L Axis and NOTCH1 in pancreatic cancer","volume":"11","author":"Lacalle-Gonzalez","year":"2023","journal-title":"Biomedicines."},{"key":"2026060105301018000_67.6.943.55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2312"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.271302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:18:21Z","timestamp":1785269901000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.271302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,1]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.2967\/jnumed.125.271302"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.271302","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}